New Antiviral Successfully Halts Spread of Deadly Measles-Like Virus

An experimental oral antiviral called GHP-88310 has shown the ability to stop the spread of a measles-like virus in animal models, researchers said. The candidate is described as a broad-spectrum viral polymerase inhibitor and was reported to block transmission through both direct contact and airborne routes.

The results point to a possible additional tool for outbreak response, particularly when used around the time of exposure. Researchers said they are now preparing the drug candidate for formal clinical trials, and the work is backed by federal health research funding.

How GHP-88310 performed in animal testing In the animal studies described by researchers In the animal studies described by researchers, GHP-88310 prevented transmission when given shortly before exposure and also when administered shortly after exposure. Officials involved in the work said the drug’s mechanism targets viral polymerase activity, a core step in replication, positioning it as a potential broad-spectrum option against viruses in the same family. Beyond blocking spread, the treatment was reported to shorten the duration of illness in infected subjects. Researchers also said it reduced the period during which infected subjects remained contagious, a point that matters for limiting secondary cases during outbreaks. Why researchers see a role alongside vaccination Researchers said the findings suggest a possible “secondary intervention” to complement vaccination strategies during public health outbreaks. The proposed use described in the report is not as a replacement for immunization, but as an additional measure that could be deployed in outbreak settings where exposures occur and where quarantine requirements can be extensive.

Measles control has historically relied on vaccination as Measles control has historically relied on vaccination as the primary prevention tool, with outbreak management often involving case isolation and quarantine for contacts. The source material links this new approach to the practical burden of prolonged quarantine requirements, describing substantial economic and social costs when large numbers of contacts must restrict movement.

Rising outbreaks across North America since 2025

The report says measles outbreaks have increased across North America since 2025, with significant hospitalizations and mortality. It adds that the virus’s reemergence has challenged regional elimination status and has contributed to broader disruption tied to containment measures.

Researchers framed the current work as relevant to paramyxovirus outbreak management more broadly, given the drug’s polymerase-inhibiting approach and the stated of expanding options beyond vaccination and non-pharmaceutical controls.

Next steps and remaining unknowns

Researchers said they are preparing GHP-88310 for formal clinical trials, a step needed to assess safety, dosing, and effectiveness in people. The source material does not provide a clinical timeline, trial design details, or human efficacy data, leaving uncertainty about how the animal results will translate to real-world outbreak use.

Still, officials said the federally supported development could signal a shift toward pairing vaccines with targeted antivirals as part of preparedness for measles-like and other paramyxovirus outbreaks.